Brainstorm Cell Therapeutics (OTCQB: BCLI) continues to be on fire. Trading today represented the highest dollar volume for the year and the second highest share volume for the year. With over 4 million shares traded, the stock has just crossed into the highest pricing in about three years.
What’s happening to make this surge in price and shares traded?
- Jun 10, 2014 BrainStorm Expands Pipeline With Initiation of Pre-Clinical Study in Autism
- Jun 9, 2014 BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
- Jun 6, 2014 First Patient Enrolled in BrainStorm’s Phase II ALS Trial at Massachusetts General Hospital
- Jun 5, 2014 BrainStorm Hosting Conference Call to Update Shareholders on Major Developments
- Jun 5, 2014 Positive Interim Phase IIa ALS Data With BrainStorm’s NurOwn Presented at Joint Congress of European Neurology
- May 29, 2014 BrainStorm Announces Redemption of Outstanding Warrants for Cash
- May 27, 2014 BrainStorm to Present Phase IIa ALS Clinical Trial Data at the Joint Congress of European Neurology
- May 19, 2014 BrainStorm Cell Therapeutics Presenting at Multiple Upcoming Conferences
- Apr 29, 2014 FDA Approves Clinical Trial of BrainStorm Cell Therapeutics’ ALS Treatment
- Apr 28, 2014 FDA Approves Commencement of BrainStorm’s Phase II ALS Clinical Trial in U.S.
Pages: 1 2